We are live on
!
Find out more
GC
Grace Capital Portfolio holdings
AUM
$168M
1-Year Est. Return
21.6%
This Fund
S&P 500
This Quarter
Est. Return
+5.41%
1 Year Est. Return
+21.6%
3 Year Est. Return
+126.68%
5 Year Est. Return
+161.89%
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$74.2M
(+40%)
Cap. Flow
+$60.4M
Cap. Flow
% of AUM
23.06%
Top 10 Holdings %
Top 10 Hldgs %
27.97%
Holding
236
New
148
Increased
23
Reduced
45
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$8.58M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$7.26M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$5.88M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$4.5M |
| 5 |
Visa
V
|
+$3.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Check Point Software Technologies
CHKP
|
+$4.78M |
| 2 |
Novartis
NVS
|
+$4.73M |
| 3 |
Citigroup
C
|
+$3.89M |
| 4 |
Enterprise Products Partners
EPD
|
+$3.74M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$3.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.43% |
| 2 | Technology | 18.17% |
| 3 | Financials | 14.51% |
| 4 | Consumer Discretionary | 9.11% |
| 5 | Energy | 7.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14M | 5.34% |
+98,939
| New | +$4.5M |
|
|
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $8.8M | 3.36% |
+177,304
| New | +$8.58M |
|
3
Apple
AAPL
$4.9T
| $8.05M | 3.08% |
173,984
+25,548
| +17% | +$1.16M |
|
4
Microsoft
MSFT
$2.93T
| $7.67M | 2.93% |
77,775
-6,298
| -7% | -$610K |
|
|
5
iShares Russell 2000 ETF
IWM
$82.2B
| $7.43M | 2.84% |
+45,387
| New | +$7.26M |
|
6
JPMorgan Chase
JPM
$907B
| $6.96M | 2.66% |
66,812
-3,850
| -5% | -$422K |
|
|
PTLA
7
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $5.81M | 2.22% |
+153,729
| New | +$5.88M |
|
8
Bank of America
BAC
$430B
| $5.59M | 2.13% |
198,276
-66,410
| -25% | -$1.98M |
|
9
Cisco
CSCO
$441B
| $4.72M | 1.8% |
109,781
-4,707
| -4% | -$206K |
|
10
Pfizer
PFE
$143B
| $4.21M | 1.61% |
122,310
-24,063
| -16% | -$822K |
|
11
Zions Bancorporation
ZION
$10.6B
| $3.98M | 1.52% |
75,640
-34,888
| -32% | -$1.93M |
|
12
Walmart Inc
WMT
$909B
| $3.91M | 1.49% |
136,923
-12,159
| -8% | -$346K |
|
|
FITB
13
Fifth Third Bancorp
FITB
$52.6B
| $3.9M | 1.49% |
135,950
-37,146
| -21% | -$1.18M |
|
14
SiriusXM
SIRI
$10.3B
| $3.85M | 1.47% |
56,843
+10,483
| +23% | +$708K |
|
|
STMP
15
DELISTED
Stamps.com, Inc.
STMP
| $3.81M | 1.45% |
15,035
+11,979
| +392% | +$2.89M |
|
|
FISV
16
Fiserv Inc
FISV
$27B
| $3.75M | 1.43% |
50,564
-15,468
| -23% | -$1.12M |
|
|
OPLN
17
Openlane
OPLN
$4.18B
| $3.65M | 1.4% |
176,113
-67,028
| -28% | -$1.37M |
|
|
STI
18
DELISTED
SunTrust Banks, Inc.
STI
| $3.52M | 1.34% |
53,317
-39,156
| -42% | -$2.66M |
|
19
Meta Platforms (Facebook)
META
$1.64T
| $3.47M | 1.33% |
17,860
+16,093
| +911% | +$2.91M |
|
20
Warner Bros
WBD
$67.4B
| $3.44M | 1.31% |
+125,160
| New | +$2.98M |
|
|
WLL
21
DELISTED
Whiting Petroleum Corporation
WLL
| $3.44M | 1.31% |
+870
| New | +$3.01M |
|
|
22
Visa
V
$682B
| $3.14M | 1.2% |
+23,730
| New | +$3.05M |
|
23
Boeing
BA
$169B
| $3M | 1.14% |
8,931
+8,226
| +1,167% | +$2.83M |
|
24
Gilead Sciences
GILD
$167B
| $2.94M | 1.12% |
41,485
+7,315
| +21% | +$517K |
|
25
Gentex
GNTX
$5.19B
| $2.91M | 1.11% |
126,351
+47,010
| +59% | +$1.12M |
|
Similar funds
REMS
TI
NM
KM
MC
FAC
MSO
ACM
Grace Capital's Q2 2018 Portfolio in Review
As of Q2 2018, Grace Capital held 236 positions worth $262M, up 40% from $188M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Grace Capital deployed $60.4M of net new capital in Q2 2018, opening 148 new positions and adding to 23 existing holdings. Its largest new stake was MyoKardia, Inc. Common Stock: 177,304 shares worth $8.8M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 13% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Citigroup, an estimated $3.89M trimmed.
- Grace Capital's largest Q2 2018 buy was MyoKardia, Inc. Common Stock: 177,304 shares worth $8.8M.
- Grace Capital added most to Meta Platforms (Facebook) in Q2 2018, an estimated $2.91M increase.
- Grace Capital's biggest Q2 2018 reduction was Citigroup, cutting an estimated $3.89M.
- Grace Capital fully exited Check Point Software Technologies in Q2 2018, selling an estimated $4.78M.
- Grace Capital's ten largest holdings make up 28% of its $262M portfolio in Q2 2018.
- Grace Capital opened 148 new positions and closed 16 in Q2 2018.
- Grace Capital's portfolio value rose 40% quarter-over-quarter to $262M.
Based on Grace Capital's 13F filing for Q2 2018, filed 15 Aug 2018.